Merck and Company

MRK
Delayed Nyse - 07/19 10:00:10 pm
81.39USD
-1.57%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 2018 2019 (e)
Sales 42 294 44 670
EBITDA 15 781 18 323
Operating profit (EBIT) 13 926 15 116
Pre-Tax Profit (EBT) 8 701 12 320
Net income 6 220 10 053
P/E ratio 32,9x 20,2x
EPS ( $ ) 2,32 4,02
Dividend per Share ( $ ) 1,99 2,22
Yield 2,60% 2,73%
Reference price ( $ ) 76,410 81,390
Announcement Date 02/01/2019
11:45am
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 2018 2019 (e)
Debt 16 250 18 019
Finance - -
Operating income (EBITDA) 15 781 18 323
Leverage
(Debt/EBITDA)
1,03x 0,98x
Capital Expenditure 2 615 2 491
Book Value Per Share (BVPS) ( $ ) 10,3 10,4
Cash Flow per Share ( $ ) 4,08 5,85
Announcement Date 02/01/2019
11:45am
-
Balance Sheet Analysis
Financial Ratios
Size 2019e 2020e
Capitalization 209 550 M $ -
Entreprise Value (EV) 227 569 M $ 225 222 M $
Valuation 2019e 2020e
P/E ratio (Price / EPS) 20,2x 16,5x
Capitalization / Revenue 4,69x 4,42x
EV / Revenue 5,09x 4,80x
EV / EBITDA 12,4x 11,5x
Yield (DPS / Price) 2,73% 2,90%
Price to book (Price / BVPS) 7,83x 7,41x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) 33,8% 34,9%
Operating Leverage (Delta EBIT / Delta Sales) 1,52x 1,56x
Net Margin (Net Profit / Revenue) 22,5% 26,1%
ROA (Net Profit / Asset) 13,7% 16,2%
ROE (Net Profit / Equities) 44,2% 49,1%
Rate of Dividend 55,3% 47,8%
Balance Sheet Analysis 2019e 2020e
CAPEX / Sales   5,58% 5,35%
Cash Flow / Sales 33,7% 33,8%
Capital Intensity (Assets / Sales) 1,64x 1,61x
Financial Leverage (Net Debt / EBITDA) 0,98x 0,79x
Price Earning Ratio
BNA & Dividende